How to access Ebglyss for moderate-to-severe atopic dermatitis in adults and adolescents 12 and older from Saudi Arabia: 2026 pathway via SFDA-coordinated registration, the MOH dermatology network, and named-patient import where required | Reserve Meds
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Saudi Arabia operates the largest dermatology specialty network in the GCC. King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh and Jeddah anchor the academic medical centre layer with deep adult and adolescent dermatology coverage. King Saud Medical City Riyadh, King Abdulaziz Medical City (NGHA), Prince Sultan Military Medical City, King Khalid University Hospital, King Fahad Specialist Hospital Dammam, the Dr Sulaiman Al Habib network across major cities, the Saudi German Hospital network, Dr Soliman Fakeeh Hospital Jeddah, and the Mouwasat Hospital network round out the prescribing landscape. All run dermatology programmes treating moderate-to-severe atopic dermatitis in adults and adolescents. Ebglyss (lebrikizumab-lbkz, Eli Lilly and Company) is the humanized IgG4 monoclonal antibody that binds soluble interleukin-13 (IL-13) with high affinity and blocks IL-13 receptor signalling. FDA approval landed in September 2024 for moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older weighing at least 40 kg. Saudi SFDA (Saudi Food and Drug Authority) registration for Ebglyss is in early rollout; most Saudi patients in 2026 access Ebglyss via the named-patient European or US import pathway while SFDA in-country registration catches up. For a Saudi-resident patient whose moderate-to-severe atopic dermatitis has plateaued on conventional topical therapy or who has had inadequate response or tolerability issues on a prior biologic, the operational question in 2026 is whether Ebglyss is the right fit for the patient, how the prescription is sourced and dispensed under the import pathway, what insurance will cover, what pre-treatment screening looks like, and how the family handles the every-2-week induction-and-loading routine that transitions to every-4-week maintenance dosing in responders at week 16.
This page explains how the pathway works in 2026 for a Saudi-resident patient. It is concierge documentation written for a family already in conversation with a treating dermatologist who wants the operational reality laid out plainly. It includes an explicit vs-Dupixent positioning section because Dupixent is the other established biologic option for moderate-to-severe atopic dermatitis and the most common comparator question we field.
Why Ebglyss, and why now
Ebglyss is lebrikizumab, a humanized IgG4 monoclonal antibody originally developed by Genentech and Roche, in-licensed by Dermira, and now held by Eli Lilly and Company. The molecule binds soluble IL-13 with high affinity. By sequestering IL-13, lebrikizumab blocks the formation of the IL-13Ra1 / IL-4Ra heterodimer signalling complex on target cells. Lebrikizumab does NOT bind IL-4 and does NOT block IL-4 signalling through the type I IL-4 receptor. This is the central mechanistic distinction versus Dupixent (dupilumab), which targets IL-4Ra directly and thereby blocks signalling of both IL-4 and IL-13.
IL-13 is the dominant cytokine driving epidermal barrier dysfunction, keratinocyte proliferation, and the Th2 inflammatory cascade in atopic dermatitis. By selectively blocking IL-13 signalling, lebrikizumab dampens the chronic itch and inflammation cycle that defines moderate-to-severe atopic dermatitis. Itch reduction is often noticeable within 2 weeks. EASI-75 response is achieved in approximately 50 to 60 percent of patients by week 16 in monotherapy pivotal trials, and in approximately 70 percent in combination with topical corticosteroids.
FDA approval September 2024. EMA approval November 2023. SFDA registration is in early rollout in 2026. The September 2024 FDA approval places Ebglyss in the less-than-24-month NPP-pathway-primary framing window for Saudi Arabia in 2026: the named-patient European or US import pathway is the primary access mechanism, with SFDA domestic-registration framing as the secondary scenario where SFDA registration has progressed.
Reserve Meds does not promote one biologic over another. The competing class includes Dupixent (dupilumab, anti-IL-4Ra), Adbry (tralokinumab, anti-IL-13 for adult AD), Cibinqo (abrocitinib JAK1), Rinvoq (upadacitinib JAK1), and Nemluvio (nemolizumab, anti-IL-31Ra for prurigo nodularis and AD). The JAK inhibitor class carries a class black-box warning. Choice across these alternatives is the central clinical decision and sits with the treating dermatologist.
What Ebglyss is, in plain language
Ebglyss is a subcutaneous injection. It is not an infusion and does not require a hospital infusion suite. After an initial training session at the prescribing dermatologist's clinic or with a Lilly-coordinated nurse educator, most adult patients self-administer at home using the Ebglyss pre-filled pen or pre-filled syringe at 250 mg per device. Adolescent patients (12 years and older, at least 40 kg) self-administer after training or are administered by a caregiver. The drug requires cold-chain storage at 2 to 8 degrees Celsius; the carton is stable at room temperature for up to 7 days unopened (a shorter window than Dupixent at 14 days).
The dosing schedule:
- Week 0: 500 mg loading dose (two 250 mg injections at separate sites at the same visit). - Week 2: 500 mg (two 250 mg injections). - Week 4, 6, 8, 10, 12, 14: 250 mg every 2 weeks. - Week 16 response assessment: responders (IGA 0 or 1 with at least 2-point reduction, or other meaningful clinical response) transition to 250 mg every 4 weeks maintenance dosing. Partial responders or non-responders continue 250 mg every 2 weeks through week 24 and reassess.
The transition from q2w induction-and-loading to q4w maintenance in responders is a dosing-frequency distinction versus Dupixent (q2w throughout for adult AD). For a responder, q4w maintenance delivers 13 injections per year rather than 26.
This is not a short-course therapy. Ebglyss is taken for as long as it controls the disease.
Eligibility at a Saudi dermatology clinic
For Saudi-resident patients, the prescribing dermatologist applies FDA and EMA criteria with local MOH and insurance adaptation:
1. Moderate-to-severe atopic dermatitis confirmed by IGA, EASI, BSA, and DLQI (or POEM in adolescents). Documented inadequate response to topical prescription therapies or contraindication. 2. Age 12 years or older. 3. Body weight at least 40 kg. Younger or lower-weight paediatric patients are referred toward Dupixent (FDA-approved down to 6 months) or the JAK inhibitor class. 4. Treatment history. Documented prior failure of (or contraindication to) appropriate topical prescription therapy. CCHI commercial insurers commonly require documented prior systemic therapy (oral corticosteroid courses, cyclosporine, methotrexate) or prior biologic or JAK inhibitor trial before approving a switch to Ebglyss. 5. Baseline laboratory panel. CBC with eosinophil count, comprehensive metabolic panel, total IgE (informative not gating), pregnancy test for women of reproductive potential. 6. Helminth infection screen for patients with epidemiologic risk. Treat any pre-existing helminth before initiation. 7. Active serious infection is a reason to defer initiation. 8. Vaccination status review. Live vaccines not recommended during therapy. Inactivated vaccines permitted and recommended. 9. Conjunctivitis history review. Approximately 7 percent of patients develop conjunctivitis on Ebglyss in pivotal trials (lower than Dupixent at approximately 10 to 20 percent). Patients with a history of conjunctivitis or active conjunctivitis at baseline have an ophthalmology co-management plan. 10. Pregnancy and lactation discussion for women of reproductive potential.
A Saudi patient should arrive at the biologic conversation with the most recent dermatology documentation (current EASI, IGA, BSA, DLQI scores; photographs of involved skin; complete treatment history including topical, systemic, and any prior biologic or JAK inhibitor trial), baseline screening labs, helminth and TB screening where indicated, vaccination record, and insurance pre-authorisation paperwork.
The Saudi prescribing and supply picture, plainly
SFDA registration status for Ebglyss is verified at intake. As a September 2024 FDA approval, Ebglyss is in early SFDA registration rollout in 2026. NUPCO handles MOH and military hospital procurement supply chain for registered drugs at scale; for Ebglyss, the in-country supply rollout depends on SFDA registration progress. The pathway:
1. Prescribing physician: a Saudi board-certified dermatologist or paediatric dermatologist. Major Saudi prescribing centres include KFSHRC Riyadh and Jeddah, King Saud Medical City Riyadh, KAMC NGHA, Prince Sultan Military Medical City, King Khalid University Hospital, King Fahad Specialist Hospital Dammam, Dr Sulaiman Al Habib network, Saudi German Hospital network, Dr Soliman Fakeeh Hospital, Mouwasat Hospital network. 2. Pharmacy dispensing: - Where SFDA registration has progressed: hospital outpatient pharmacy or licensed community pharmacy with cold-chain handling. Ebglyss requires 2 to 8 degree Celsius transport and storage. NUPCO-supplied MOH and military pharmacies dispense via the national supply chain where applicable; private hospital and community pharmacies dispense via commercial supply. - Where SFDA registration has not progressed (the majority case in 2026): named-patient European or US import pathway under the SFDA named-patient framework. The treating dermatologist's office documents the clinical case; the import is processed under SFDA approval. Supply lands at the prescribing hospital outpatient pharmacy under cold-chain handling. 3. Insurance pre-authorisation: MOH coverage for Saudi nationals routes through the MOH facility network with pre-authorisation handled internally; CCHI (Council of Cooperative Health Insurance) governs commercial insurance for residents through Bupa Arabia, Tawuniya, MedGulf, AXA Cooperative, Allianz SF, and others. Coverage patterns for Ebglyss in 2026 vary because of the recency of FDA approval and the SFDA-registration timing; pre-authorisation paperwork commonly requires documented severity, documented prior topical and possibly systemic therapy failure, and prior biologic or JAK inhibitor trial documentation in some cases. Patients on the named-patient import pathway should expect additional pre-authorisation discussion around import costs and supply continuity. 4. Self-injection training: typically a single supervised session at the prescribing dermatologist's clinic or via a Lilly-coordinated nurse educator visit. Most adult patients are comfortable with self-injection after 1 to 2 sessions. Adolescents 12 and older self-administer after training, or are administered by a caregiver. 5. Ongoing monitoring: dermatology follow-up at week 4, week 12, and week 16 (for the response-assessment visit). Quarterly through year one for stable responders, less frequent thereafter. Conjunctivitis surveillance at every visit. Eosinophil count at baseline and periodically.
The 2026 pathway, step by step
Week 0 to 1: Reserve Meds builds the documentation pack with the treating dermatologist's office. We collect current EASI, IGA, BSA, DLQI scores, photographs of involved skin, complete treatment history, baseline screening labs, helminth screen where indicated, vaccination record, and insurance card details. The prescribing office submits pre-authorisation and, where applicable, initiates the named-patient import paperwork.
Week 1 to 6: pre-authorisation review. Named-patient European or US import processing if applicable. CCHI commercial insurers typically turn pre-authorisation for a recent biologic around in 4 to 6 weeks; MOH pre-authorisation for nationals runs in parallel.
Week 6 to 8: first dispensing. The 500 mg loading dose (two 250 mg injections at separate sites at the same visit) and the self-injection training session are completed.
Week 2 of therapy: second 500 mg loading dose.
Week 4 through week 14: 250 mg q2w. Reserve Meds coordinates cold-chain delivery of the next month's supply.
Week 16: response assessment. Responders transition to 250 mg q4w maintenance. Less than IGA 0 or 1 means continue q2w through week 24; reassess.
Week 24 and beyond: responders continue q4w maintenance. Quarterly dermatology follow-up through year one. Patients with inadequate response by week 24 may switch within the type 2 inflammation biologic class, to a JAK inhibitor, or back to systemic therapy.
Cost band and insurance positioning
US WAC list price for Ebglyss in 2026 is approximately USD 3,400 per 250 mg device. The induction-and-loading phase (week 0 through week 14, 10 injections) is approximately USD 34,000 at list. The q4w maintenance phase for responders is approximately USD 44,000 per year at list.
At 2026 indicative cross rates, the SAR-equivalent annual cost band for the q4w maintenance responder regimen is approximately SAR 150,000 to 210,000 at list price. The induction-and-loading phase adds approximately SAR 130,000 to 155,000 in the first year. Pre-authorisation reduces out-of-pocket exposure substantially for covered patients. The annual q4w maintenance cost band is roughly one-half of the Dupixent every-2-week adult regimen on an annual basis.
For Saudi nationals on MOH coverage, the pre-authorisation conversation needs to start before the first dispensing. Commercial covers under CCHI (Bupa Arabia, Tawuniya, MedGulf, AXA Cooperative, Allianz SF) vary; the prescribing dermatologist's office is the gating step.
What to expect on Ebglyss
Itch reduction is often noticeable within the first 2 weeks. EASI-50 in roughly half of patients by week 4. At week 16 in monotherapy pivotal trials (ADvocate-1 and ADvocate-2), EASI-75 in approximately 50 to 60 percent and IGA 0 or 1 with at least 2-point reduction in approximately 33 to 43 percent. In combination with topical corticosteroids (ADhere), EASI-75 at week 16 approximately 70 percent. Sleep quality and DLQI improvement usually parallel EASI improvement.
The week 16 response-assessment visit determines transition to q4w maintenance versus continued q2w. Responders on q4w maintenance maintained EASI-75 in approximately 80 percent of patients through week 52 in extension data. Patients re-randomised to placebo at week 16 lost response within several weeks.
The first 4 to 16 weeks are the highest-vigilance window for response assessment and conjunctivitis surveillance. Patients not responding by week 16 continue q2w through week 24 with reassessment; switch options include Dupixent or Adbry within the biologic class, abrocitinib or upadacitinib in the JAK inhibitor class, or return to systemic therapy.
What to monitor
The most clinically distinctive Ebglyss monitoring item is conjunctivitis, at approximately 7 percent in pivotal trials (lower than Dupixent at approximately 10 to 20 percent). Bilateral red eye, itch, tearing, occasional photophobia. Most cases mild to moderate; respond to lubricants, lid hygiene, and topical corticosteroid drops under ophthalmology supervision. Ophthalmology referral at first sign that does not resolve within 48 hours.
Eosinophil count at baseline and periodically. Transient eosinophilia common and usually benign.
Injection-site reactions: typically mild redness, swelling, or pain at the injection site; usually transient. Site rotation reduces incidence.
Helminth surveillance for patients with epidemiologic exposure. IL-13 blockade may impair host response.
Hypersensitivity including rare anaphylaxis: stop therapy if it occurs.
Live vaccines should be avoided during therapy.
Long-term safety data approximately 2 years post-FDA-approval; profile reassuring with no opportunistic infection signal, no malignancy signal, no class black-box warning.
Ebglyss versus Dupixent
Both Ebglyss and Dupixent are appropriate first-line biologics for moderate-to-severe atopic dermatitis in adults and adolescents 12 and older. Reserve Meds does not promote one over the other. The prescribing dermatologist's choice sits on several axes:
- Mechanism: Ebglyss is IL-13 selective; Dupixent is IL-4Ra targeting (blocks both IL-4 and IL-13). - Indication breadth: Dupixent carries six FDA-approved indications; Ebglyss is dermatology-only for AD. For patients with comorbid type 2 inflammation conditions, Dupixent may treat multiple conditions simultaneously. - Age range: Dupixent down to 6 months for AD; Ebglyss 12 and older at 40 kg and above. Younger paediatric patients require Dupixent. - Conjunctivitis rate: approximately 7 percent on Ebglyss versus approximately 10 to 20 percent on Dupixent in AD trials. - Maintenance dosing frequency: Ebglyss responders q4w from week 16; Dupixent adult AD q2w throughout. - Cost band: Ebglyss q4w maintenance roughly half the annual list of Dupixent q2w adult AD. - Long-term safety dataset: Dupixent 7-plus years post-marketing; Ebglyss approximately 2 years post-FDA. Both profiles reassuring. - Saudi access pathway: Dupixent broadly SFDA-registered for adult AD since 2018; Ebglyss in early SFDA registration rollout, most 2026 patients access via named-patient European or US import.
The clinical decision sits with the treating dermatologist based on response history, conjunctivitis tolerance, dosing-frequency preference, and access.
Religious, ethical, and family-logistics framing
Ebglyss is a humanized IgG4 monoclonal antibody produced in mammalian cell culture. No donor element, no human or animal source material in the active ingredient. The classical analogy to vaccines and other recombinant biologics holds in Saudi Islamic medical ethics. Excipient sourcing varies by manufacturer batch; patients with specific halal-certification requirements should ask the dispensing pharmacy to confirm excipient sourcing for the current lot.
The self-injection element is the practical pressure point for some Saudi families. Adolescents 12 and older typically self-administer after training; caregivers can administer if preferred. Clinic-administered dispensing is available for families who prefer it.
Cold-chain storage in the Saudi summer climate: home refrigerator placement, insulated cold-chain bag for travel, 7-day room-temperature allowance in the original unopened carton (shorter than Dupixent at 14 days).
Moderate-to-severe atopic dermatitis in an adolescent and adult carries meaningful psychosocial-burden dimensions. Sleep disturbance from chronic itch, school or work absenteeism, body-image concerns, social withdrawal, anxiety, and depression in patients and parents. The clinical conversation addresses these dimensions and includes referral to behavioural health support where indicated. Lebrikizumab itself has no CNS or mood signal; the psychosocial burden is from the underlying chronic AD.
Ramadan considerations: the q2w induction-and-loading and q4w maintenance regimens are unaffected by fasting.
Hajj and Umrah travel: meningococcal conjugate (inactivated) permitted and recommended.
When Ebglyss is the wrong drug
- Age under 12 or weight under 40 kg: not eligible. Younger paediatric AD goes to Dupixent. - Mild atopic dermatitis: Ebglyss is for moderate-to-severe with documented inadequate response to topical therapy. - Active conjunctivitis with poor ophthalmology support: ophthalmology co-management plan before initiation. - Active helminth infection: treat before initiation. - Hypersensitivity to lebrikizumab or excipients: contraindicated. - Active serious infection: defer. - Need for live vaccination in near term: complete then initiate. - Pregnancy: limited data; individualised decision. - Comorbid type 2 inflammation conditions: may favour Dupixent (multi-indication).
Alternative biologics for adult and adolescent AD: dupilumab, tralokinumab (adult only), nemolizumab. JAK inhibitor alternatives: abrocitinib, upadacitinib (class black-box warning).
What Reserve Meds does on this case
We are a US-based concierge coordinator. We are not the prescriber and not the dispensing pharmacy. On a Saudi Ebglyss case we build the documentation pack with the treating dermatologist's office, confirm SFDA registration status for Ebglyss (and the appropriate dispensing pathway, including named-patient European or US import where required), run the insurance pre-authorisation conversation alongside the clinical conversation, coordinate the cold-chain supply logistics for ongoing maintenance dispensing, organise self-injection training and the baseline screening, set up the ophthalmology co-management plan where indicated, and stay with the case through the first year of dosing with handoff to the local prescriber. Clinical decisions remain with your treating dermatologist.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating dermatologist.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.